Overview
SGMT market data
Price History
SGMT price chart · 1M
- O
- 10.95
- H
- 10.95
- L
- 10.55
- C
- 10.78
- Vol
- 24,040.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $10.95
- Previous Close
- $10.86
- Day High
- $10.95
- Day Low
- $10.55
- 52 Week High
- $11.12
- 52 Week Low
- $6.27
- 7 Day Return
- +6.05%
- 30 Day Return
- +48.28%
- 90 Day Return
- +47.67%
- 1 Year Return
- +25.28%
- Daily Notional Volume
- $259.2K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.58 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,393.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.50 – $11.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $567.8M · P/B 1.65.
Company News
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price TargetBenzinga · Aug 25, 2026, 3:30 PM
Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026Benzinga · Aug 25, 2026, 11:02 AM
Sagimet Biosciences shares are trading higher after Citizens raised its price target on the stock from $12 to $29.Benzinga · Aug 14, 2026, 6:11 PM
Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29Benzinga · Aug 14, 2026, 1:01 PM
Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026Benzinga · Aug 13, 2026, 11:06 AM
8-K filing — Sagimet Biosciences Inc. (SGMT)SEC EDGAR · Aug 13, 2026, 11:05 AM
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56Benzinga · Aug 12, 2026, 3:56 PM
Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) EstimateBenzinga · Aug 11, 2026, 11:46 AM
Sagimet Biosciences Added To Broad-Market Russell 3000 Index And Small-Cap Russell 2000 IndexBenzinga · Jun 29, 2026, 11:20 AM
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® IndexesGlobenewswire Inc · Jun 29, 2026, 11:15 AM